^
    Back
    Association details:
    Biomarker:ABCB1 G1236T + ABCB1 G2677T
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Oncology
    Title:

    ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy

    Published date:
    08/16/2012
    Excerpt:
    PFS was significantly longer in ABCB1 1236CC and/or 2677TT carriers compared to the others (p = 0.006)...Our data support that ABCB1 polymorphisms may predict PFS after first-line TH chemotherapy in patients with HER2-positive MBC.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1159/000341359